Won’t change much.
This morning Abbott received word that the FDA has cleared the Libre 2 and Libre 3 for integration into an automated insulin dosing (AID) system. Per their press release – “Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has cleared its FreeStyle Libre 2 and FreeStyle Libre 3 integrated continuous glucose monitoring (iCGM) system sensors for integration with automated insulin delivery (AID) systems. Abbott modified the...
Layoffs, investigation what’s up at Abbott?
Since most people aren’t aware of Abbott’s history in CGM let’s go backward before we go forward. In February of 2004 when Abbott acquired Therasense for $1.2 Billion hidden in this deal was the Navigator. Keep in mind that back in 2004 BGM ruled the glucose monitoring world and CGM was still a dream. Yet CGM was coming, and the Navigator was considered the best of the bunch. In June 2005...
It won’t help.
Before we get into the gist of today’s post a short history of acquisitions in the insulin pump space. Way back in the day there were two major players MiniMed and Disetronic. Back in 2003 Roche paid $1.2 Billion for Disetronic and promptly ran the company into the ground. Not content to run just one insulin pump company into the ground Roche doubled down and in 2010 spent another $160 million...
What then?
With all this hype over the supposed Apple Watch which will measure glucose non-invasively it’s time to speculate as to what would really happen if they got the damn thing to work. Now we’ll state upfront that we don’t think Apple is anywhere near close to making this happen and highly doubt it will ever happen. That this quest has going on for years and is no closer to the...
Is there a way out?
Now that all of the insulin pump companies have reported here is what we know. Insulet has firmly established themselves as the leader in the category while Medtronic and Tandem are struggling to remain relevant. So, the question becomes barring a sale how do Medtronic and Tandem remain relevant? How do they effectively compete without crippling their revenue model? Let’s make something very clear as it’s a myth being spread by both Medtronic...
Alone at the top
Before we get into the outstanding results released by Insulet we have to gloat just a little with the results released by Teladoc. This from an article posted on Healthcare Drive “Teladoc Health reported a historic net loss in 2022 of $13.7 billion off revenue of $2.4 billion, mostly from an impairment charge related to the shrinking value of its Livongo acquisition.” Long ago we predicted that one of two things would...
Recycled News
Not sure whether I should be laughing, crying or both but this story about Apple the maker of all things way cool and whiz bang being oh so close to adding CGM to the Apple Watch does crack me up. This is just recycled news and will NOT repeat NOT be happening anytime soon. Heck the Cleveland Browns or LA Chargers will win a Superbowl before this happens. But you...